With a rapidly aging global population and improvement of outcomes with newer multiple
sclerosis (MS)-specific disease-modifying therapies (DMTs), the epidemiology of MS has …

Introduction: The successful development of anti-inflammatory disease-modifying treatments
(DMT) significantly improved disease outcomes and longevity of persons with multiple …

Abstract Purpose of Review The purpose of this review is to discuss the interaction between
aging, progressive disease course, disability worsening, and treatment strategies in multiple …

Multiple sclerosis (MS), an inflammatory demyelinating and neurodegenerative disease of
the central nervous system, usually begins between the ages of 20 and 49 years, though in …

Background There is a lack of knowledge of disease course, prognosis, comorbidities and
potential treatments of elderly MS patients. Objective To characterize the disease course …

Age and the risks of high-efficacy disease modifying drugs i... : Current Opinion in
Neurology Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis …

Background: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are approved
for the treatment of disease activity and are effective in reducing relapses and new magnetic …

Importance The prevalence of multiple sclerosis (MS) and aging MS patients is increasing
worldwide. There is a need to better understand this MS sub-population, which historically is …

The available clinical evidence examining DMT discontinuation in older people with MS
remains inconclusive. More robust evidence from clinical trials and real-world data will be …

Background and purpose To investigate the relation of age at disease onset and clinical
outcomes across the lifespan from adolescence in patients with multiple sclerosis (MS) on …